How DataGateway unified oncology data for real-world insights & market intelligence
November 26, 2025 | DataGateway, Healthcare Data Analytics
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
The Challenge
A global biopharmaceutical company needed a clearer understanding of real-world treatment patterns in a complex oncology market.
The organization had access to a wide range of real-world data sources – from insurance claims and lab results to specialty pharmacy feeds. However, each dataset told only part of the story. Inconsistencies in data formats, timing, and patient tracking made it difficult to answer critical business questions such as:
- How many patients are actively being treated in each line of therapy?
- Which treatment combinations are emerging across geographies and time?
- How do market trends align with sales performance?
The client needed an integrated, validated data solution that would bring these disparate sources together into a single, trustworthy framework – one that could support analytics, forecasting, and commercial decision-making.
Our Solution
Using our DataGateway platform to integrate multiple real-world data sources into a unified, insight-ready dataset.
Using configurable pipelines and standardized business logic, we performed the following key functions:
- Data unification: Combined multiple claims, laboratory, and specialty pharmacy datasets into a single patient-level data structure.
- Standardization and validation: Applied consistent business rules to ensure data quality, alignment, and traceability across all sources.
- Clinical and analytical logic: Reconstructed treatment “episodes” and “lines of therapy,” accurately capturing how patients progressed through treatment sequences.
- Triangulation and benchmarking: Validated integrated outputs against external epidemiology and reference datasets to ensure accuracy and completeness.
The resulting data asset provided a comprehensive view of patient populations, treatment pathways, and market dynamics, accessible through flexible analytics tools for ongoing reporting and insight generation.
The Results
By unifying and standardizing complex oncology data, the client gained a complete and reliable view of the market that had previously been out of reach.
Key outcomes included:
- Expanded visibility: Integration increased identifiable patient coverage by more than 80% compared to any single data source.
- Faster insights: Data refresh and delivery cycles shortened from months to weeks, enabling near-real-time monitoring of treatment trends.
- Higher accuracy: Integrated outputs were consistently validated against external benchmarks, improving confidence in forecasts and commercial models.
- Cross-functional alignment: Medical, brand, and commercial teams could now access a shared, harmonized dataset – strengthening collaboration and strategic decision-making.
The unified view of real-world oncology data helped the client identify emerging treatment behaviors, optimize targeting strategies, and strengthen its understanding of market performance – supporting both clinical and commercial objectives.
Contact us.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Intelligent Commercialization™ across the pharma lifecycle
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
Four steps to a smarter congress strategy: A practical guidebook
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Infographic: Are data blind spots putting your launch at risk?
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
From activity to impact: 5 takeaways from MAPS Americas 2026
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio launches Intelligent Congress: Turning medical event investment into measurable impact
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…